HPLIVING TECH (01682.HK): Subsidiary Grants HK$30m Revolving Loan Facility
NewTimeSpace News: On 21 October 2026 (after trading hours), Hang Pin Living Technology Company Limited (stock code: 01682) announced that its wholly-owned subsidiary Gold Peak Finance Limited, as lender, entered into a financing agreement with the borrower Huafu International (Hong Kong) Financial Holdings Limited, under which Gold Peak agreed to provide a revolving loan facility of up to HK$30,000,000.
The facility has an availability period of up to 12 months, automatically extended by three months on each three-month review date unless either party gives at least 10 business days' written notice before the review date of its election not to extend; interest accrues at one-month HIBOR plus 0.5% per annum; if either party elects not to extend, the facility matures on the review date and the borrower must repay all outstanding principal and accrued interest within five business days after the early repayment date; the borrower may re-borrow repaid amounts, provided the outstanding principal does not exceed HK$30,000,000; the facility is funded from the Group's internal resources.
The borrower is a wholly-owned subsidiary of Huafu Securities Co., Ltd., a state-owned financial institution in Fujian Province, China, approximately 46.72% owned by Fujian Provincial Financial Investment Co., Ltd. (wholly owned by the Fujian Provincial Department of Finance), with the remaining approximately 53.28% held by other shareholders. The borrower group holds SFC Type 1, Type 4, Type 6 and Type 9 licences and is a qualified trading and clearing participant of the Stock Exchange. The borrower is an independent third party, and the Group completed due diligence and credit review before signing.
Under the Listing Rules, as one or more applicable percentage ratios exceed 5% but all are below 25%, the financing agreement constitutes a discloseable transaction subject to the reporting and announcement requirements; as the assets ratio of the outstanding amounts drawn exceeds 8%, the Company is also required to disclose details of the loan to an entity under Rules 13.13 and 13.15.
- SUNFONDA GP (01771.HK): Further Valuation Details on Disposal; Circular Extended to 25 November
- SIHUAN PHARM (00460.HK): Xuanzhu Bio's Phase III Anlarazole Data Presented at UEG Week
- XUANZHUBIO-B (02575.HK): Phase III Oesophagitis Data for Anlarazole Sodium Presented at UEG Week
- KINTOR PHARMA-B (09939.HK): KT-939 Receives Notice of Invention Patent Grant
- CH MODERN D (01117.HK): Exercises Redemption Right to Buy 25.4% of Wuhe Unit for About RMB 667.5mn